Granules India Limited (BOM:532482)

Market Cap	155.80B +32.7%
Revenue (ttm)	50.92B +14.2%
Net Income	5.45B +13.8%
EPS	22.49 +13.9%
Shares Out	247.80M
PE Ratio	27.96
Forward PE	21.73
Dividend	1.50 (0.24%)
Ex-Dividend Date	n/a

Volume	135,807
Average Volume	84,159
Open	610.05
Previous Close	608.55
Day's Range	609.00 - 640.00
52-Week Range	412.05 - 640.00
Beta	-0.04
RSI	64.73
Earnings Date	May 15, 2026

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 4,066
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532482

Financial Performance

In fiscal year 2025, Granules India's revenue was 44.82 billion, a decrease of -0.55% compared to the previous year's 45.06 billion. Earnings were 5.02 billion, an increase of 23.74%.